CNA FINANCIAL CORP (CNA): what the price assumes

In the published model solve dated 2026-Q2, anchored at $49.31, CNA FINANCIAL CORP (CNA) is priced for 9.5% return on equity. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-08-30 · Source: https://boothcheck.com/report/CNA

Headline

FieldValue
TickerCNA
CompanyCNA FINANCIAL CORP
Sector / IndustryFinancial Services
Current price$49.31/sh
CompositionSpecialty 42% / Commercial 48% / Life & Group 10%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisfinancials
Return on equity needed9.5%
Return on equity now11.0%
ROE gap-1.5pp
Price-to-book1.19x

Solve inputs: computed at a 8.6% cost of equity with 4% terminal growth over a 10-year stage, on common book equity (FY2026).

How unusual the bet is: within-range

ReferenceValue
vs own history+1.03σ
cohort percentile (of 78 peers)26
sustained it ~10 years at this level78%
implied end-window share0%

Valuation X-Ray

The price is supported by asset-based and earnings-power and growth-DCF value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset0.92x3justifies
Earnings1.00x1justifies
Relative0
Growth0.72x1justifies

Families that justify the price: Asset, Earnings, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.7%); the inversion above states its own rate.

Per-Model Detail (n=5)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowthno
Bank Fair Value (P/TBV)$58.150.85xyesTBVPS $40.79 × 1.43x (ROE (TTM) 11.1% / CoE 9.3%, g=5.0% (sustainable: 65% retention × ROE, 5% cap; not the terminal-growth assumption))
Relative ValuationRelativenoP/E 11x (static sector reference · 2026-04), scenarios: 9.2x / 11.0x / 12.8x (bear / base = reference held flat / bull), EV/EBITDA 22x
Simple DDMGrowthno
Two-Stage DDMGrowth$68.150.72xyesStage 1: 20% for 5yr, Stage 2: 3.5% perpetual
Simple Excess ReturnAsset$49.421.00xyesBV/sh $41.34, ROE (TTM) 11.1%, ke 9.3%
Two-Stage Excess ReturnAsset$53.850.92xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowthnoRev $15.2B, growth 3% (input: historical growth; tapered), Terminal P/S: 0.7x / 0.9x / 1.0x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelativenoEPS $4.55, growth 2% (input: historical EPS growth), PEG=5.39 (Overvalued)
Margin TrajectoryGrowthno
Earnings Power ValueEarningsno
Residual IncomeAssetno
Graham NumberAsset$65.050.76xyes√(22.5 × EPS $4.55 × BVPS $41.34) — Graham's conservative floor
EV/EBITDA RelativeRelativeno
FCF YieldEarningsno
SBC-Adj FCF YieldEarningsno
Ben Graham FormulaEarningsnoEPS $4.55 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAssetno
P/Sales SectorRelativeno
PEG Fair ValueRelativenoEPS $4.55 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$49.191.00xyesEPS $4.55 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelativeno
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Economic-Unit Decomposition (Sum Of The Parts)

The issuer is a funded financial business. Debt, interest, and cash flows are operating inputs, so industrial EV, net-debt, WACC, and free-cash-flow lenses do not apply; value the common-equity claim with book, earnings, capital, and payout economics.

UnitRoleValuation basisRevenueReported profitValue evidenceStatus
Specialtyfinancialequity$5.7bwithheldunresolved standalone equity facts required
Commercialfinancialequity$6.5bwithheldunresolved standalone equity facts required
Life & Groupfinancialequity$1.3bwithheldunresolved standalone equity facts required

No unit-level total common-equity value is stated. Each financial unit requires supported standalone common equity, normalized earnings, capital adequacy, and payout capacity. Consolidated debt, interest, and cash are operating balances, not an enterprise-to-equity bridge; company-level book, earnings, capital, and payout lenses remain the coherent cross-checks.

Solvency

FieldValue
Share count CAGR (buyback)-0.1%

Deposit/float-funded balance sheet: debt is funding, not corporate leverage, and GAAP operating cash flow follows loan flows. Net-debt, interest-coverage, and cash-burn lenses do not apply. The solvency frame for a financial is regulatory capital and payout capacity (CET1, stress buffer, dividends plus buybacks against earnings).

Bullet Takeaways

Bull Case

An insurer is not valued the way an operating company is, and once you see why, the case for this one gets simpler. A manufacturer sells a thing and books the profit. An insurer takes money now for a promise to pay later, invests the money in the meantime, and finds out years afterwards whether the price it charged was right. Its balance sheet is the product. So the question narrows to two numbers: what the company earns on its equity, and what you pay for a dollar of that equity. CNA earns about 11 percent on book on a trailing basis, and the shares change hands at about 1.34 times book. Today's price is broadly consistent with that return settling near 10.3 percent, which is slightly less than the company is earning now. The price is not asking for improvement.

The second engine has nothing to do with underwriting and is getting stronger on its own. Net investment income reached 610 million dollars in the first quarter of 2026, with the fixed income portion rising 18 million to 568 million. The FY2025 10-K shows the same direction across the full year: taxable fixed income income of 2,012 million against 1,940 million the year before, and tax-exempt of 165 million against 144 million. An insurer holds bonds bought in the past. As those bonds mature into a market with higher yields, the running income rises without anyone underwriting a single new policy. That is a mechanical tailwind, and it runs for as long as the maturity ladder does.

The international book is the part of the business quietly getting better. The 10-K reports net written premiums of 1,347 million against 1,262 million, an underwriting gain of 115 million against 76 million, and net investment income of 156 million against 131 million. An underwriting gain that grows by half while premium grows by seven percent is the signature of better risk selection rather than more risk taken.

On the long-duration life liabilities, the lever that gets overlooked is contractual. The 10-K states that for those policies "policyholders must continue to make periodic premium payments to keep the policy in force and we have the ability to increase policy premiums, subject to state regulatory approval." The regulator is a real constraint and the approvals are slow, but the block is not a fixed-price obligation. It has a repricing mechanism, and that mechanism has been used across the industry for years.

Capital return is where the arithmetic gets pleasant. About 84.6 percent of the latest fiscal year's earnings went back to shareholders as dividends plus buybacks, and the share count has been essentially unchanged over the four years to March 2026. Retaining capital only creates value when the company can earn more on it than the capital costs. At roughly 11 percent against a cost of equity near 8.7 percent that spread exists, but it is thin, and paying out most of the earnings instead of stacking them into a business trading near book is the honest response to a thin spread rather than a failure of ambition.

The underwriting result in the first quarter was bad and the reserve movement behind it was worse. What keeps the bull case standing is that neither the investment income nor the capital return depends on fixing it quickly.

Bear Case

The claim a specialty insurer makes is that it prices risk better than the market does. The first quarter of 2026 is evidence against it. The property and casualty combined ratio came in at 102.2 percent, against 98.4 percent in the same quarter a year earlier. The 10-K defines the measure plainly: "The combined ratio is the sum of the loss ratio, the expense ratio and the dividend ratio." Above 100, the insurance itself loses money, and only the investment portfolio makes the quarter work.

The deterioration was not weather. Catastrophes cost 3.6 points in the quarter against 3.8 points a year earlier, at 97 million dollars pretax in both. Strip out catastrophes and reserve movements and the underlying combined ratio still worsened, from 92.1 percent to 94.5 percent. The sharpest item is the reserve line: prior period development ran unfavourable by 4.1 points against 2.5 points, driven by excess casualty and professional liability lines written in recent accident years. Translated, policies sold in the last few years are costing more than the company assumed when it set their prices. That is precisely where an underwriting franchise is supposed to be strongest, and it is the one number an outside investor cannot check in advance.

Pricing power looks thin against that. Written rate rose 2 percent in the quarter and renewal premium change was 3 percent, with net written premium up 1 percent. Management's own remarks describe an industry "experiencing pressure on growth, rate and loss cost trends". Peer filings name the cause. W. R. Berkley warns that new entrants with "substantial infusions of capital or access to third-party capital, provide increasing competition" and that "an expanded supply of capital may lower costs for insurers". TRV describes the same money arriving from a different door, noting that "Pension and hedge funds and other entities with substantial available capital, more flexible legal structures and/or potentially lower return objectives have increasingly sought to participate". When capital with a lower required return shows up in your market, the price of the product falls to meet it, and specialised expertise stops being scarce.

CNA names the newer version of the same erosion itself. Its 10-K concedes that if industry peers use data and machine analytics more effectively, "we will be at a competitive disadvantage", and adds the blunter line that "We may lose business to competitors offering competitive insurance products at lower prices."

Now connect that to what the price assumes. Today's quote is broadly consistent with the company sustaining a return on equity around 10.3 percent, against the roughly 11 percent it earns on a trailing basis. That looks undemanding until you widen the window: across seventeen years of its own record the average return on equity is closer to 7 percent. An insurer that earns less on its equity than that equity costs is worth less than the book value of it, and the market reprices that arithmetic quickly. At about 1.34 times book there is room for the multiple to compress toward book value and below without anything dramatic happening, simply by the return drifting back to its own long-run average.

Behind the property and casualty business sits the long-duration life block, and its shape is worth stating. The 10-K puts undiscounted expected future benefit and expense payments at 31,323 million against undiscounted expected future gross premiums of 4,930 million, with a weighted average effective duration of 11 years. The gap is meant to be covered by reserves already set aside and the investment return on them. Whether it is depends on assumptions about how long people live and how much care they need, and the filing does not pretend otherwise: "Our actual experience could vary from the key assumptions used to determine future policy benefit reserves for long-term care policies." It goes on to say that resulting charges "have been and in the future could be substantial."

The last item is governance, and it is permanent rather than cyclical. Loews holds roughly 92 percent of the shares and, per the 10-K, "is in a position to control actions that require the consent of stockholders, including the election of directors, amendment of our Restated Certificate of Incorporation and any merger or sale of substantially all of our assets." Three officers of Loews sit on the board. Minority holders own a claim on the economics and no claim at all on the outcome.

Valuation

Book value is where an insurance valuation starts, because unlike a factory or a brand, most of what an insurer owns is marked to a market price every quarter. Against book of 39.87 dollars a share, today's price of 53.63 works out to about 1.34 times that equity. Tangible book, which strips the goodwill, sits at 39.33 dollars a share, so almost none of the premium above book is being paid for intangibles.

What the price embeds is a return, not a growth rate. On a five-year view at a cost of equity near 8.7 percent, today's quote is broadly consistent with the company sustaining a return on equity of about 10.3 percent, against roughly 11 percent earned on a trailing basis. Treat that as a direction rather than a measurement: a single percentage point of movement in the cost of equity shifts the required return by about 1.3 points. The notable thing is the sign. The price asks for slightly less than the company currently delivers, which is not where premium-priced equities usually sit.

The methods agree with each other to an unusual degree, and none of them finds the price expensive. The asset-value methods, which build up from book equity and the excess return earned on it, land essentially where the shares trade, with today's price about 1 percent above them. The peer-multiple methods land at the price almost exactly. The tangible-book approach the sector is actually valued on, which sets the multiple from the gap between what the company earns on equity and what that equity costs, reaches slightly above the price. Some of the forward methods land far above it, but they get there by extrapolating growth rates in the high teens and twenties that this company's own trailing earnings do not show, so the honest read is the book-value one. When every lens supports the price, the argument is no longer about whether the shares are dear. It is about why the market pays less for a dollar of this book than for a dollar of most of its peer group's.

The answer is in the three things a buyer inherits. Underwriting is currently running at a loss on the insurance itself, the life block carries decades of morbidity assumptions, and roughly 92 percent of the stock sits with one holder. Against a peer set that includes CB, TRV and WRB, this is the specialty and commercial writer the market is least willing to pay a premium over book for, and each of those three facts is a reason rather than an oversight.

Capital return is the balance-sheet frame that matters here, since deposits and reserves are funding rather than corporate borrowing. About 84.6 percent of the latest fiscal year's earnings were returned as dividends plus buybacks, with a share count essentially flat across four years, so the equity base is being held steady rather than compounded. Book value per share excluding accumulated other comprehensive income stood at 45.12 dollars at March 31, 2026 against 46.99 dollars at year-end 2025, which the company describes as a 1 percent increase once 2.48 dollars a share of dividends paid in the quarter are added back. That is the whole economic engine in one line: the book grows slowly, most of what it earns leaves as cash, and the price you pay for it is set by how much confidence you have in the reserves behind it.

Catalysts

May 4, 2026 brought the first quarter, and it was a step down. Net income was 211 million dollars, or 0.78 dollars a share, against 274 million and 1.00 dollars a share in the prior year quarter. The property and casualty combined ratio at 102.2 percent and the 4.1 points of unfavourable prior period development are the two figures that will decide how the next few prints are received, because both speak to reserve adequacy rather than to a single bad quarter of weather. The board declared its regular quarterly dividend of 0.48 dollars a share, payable June 4, 2026 to holders of record on May 18.

The most consequential scheduled event is not an earnings date at all. The FY2025 10-K states that "Annually in the third quarter, actuarial analysis is performed on policyholder morbidity, persistency, premium rate actions and expense experience" on the long-duration life liabilities. That review is where assumption changes on the long-term care block surface, and the filing is explicit that resulting charges can be large. It arrives once a year, on a known schedule, and it is the single biggest source of surprise in this company's reported results.

Rate is the third thing to watch, and it is measurable every quarter. Written rate of 2 percent and renewal premium change of 3 percent set the ceiling on how fast earned premium can outrun claims inflation. If those numbers rise, the underlying combined ratio has a path back below 100 without any change in reserving. If they stay where they are while loss costs keep climbing, the investment portfolio has to carry more of the load, which it can do for a while at current reinvestment yields and not indefinitely.

Peer Cohorts (Per Segment, With Filing Citations)

Specialty (reported)

Commercial (reported)

Life & Group (reported)

Core business (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

CNA Q1 2026 earnings release, May 4, 2026 · CNA FY2025 10-K, filed February 10, 2026

View the full interactive CNA report on boothcheck